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Anti-Inflammatory Diet for Inflammatory Bowel Disease (IBD-AID) 
Anne Barnard, MSV; Barbara Olendzki, RD, MPH; Kathryn Post, MD, MPH; Rachel Erdil, MSIII; Gin-Fei Olendzki; Anne Foley; David Cave, MD, PhD     
Department of Medicine, Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA 
•  Inflammatory Bowel Disease (IBD), including Crohn’s disease (CD) and 
ulcerative colitis (UC): Chronic, immune-mediated inflammatory conditions 
of the GI tract 
•  Increasingly linked to dysbiosis, an imbalance in the gut microbiome 
•  Pharmacological standard of care is not curative, thus driving the need and 
demand for IBD nutritional guidelines 
•  The Anti-Inflammatory Diet for IBD (IBD-AID) emphasizes anti-
inflammatory foods (prebiotic and probiotic) while limiting the intake of pro-
inflammatory carbohydrates (refined sugar, lactose, and most grains) 
•  Previous case series - 11 IBD patients showed symptomatic improvement 
and downscaling of medication regimens in all 11 patients after 4 weeks on 
the IBD-AID (Olendzki, et al. 2014) 
The purpose of this small prospective study was to further assess the efficacy 
and feasibility of the IBD-AID intervention for the treatment of CD, and to 
provide pilot data for a larger application. 
 OBJECTIVES 
•  Participants: 17 patients with biopsy-confirmed Crohn’s disease offered 
the treatment diet or standard medical care alone 
•  Intervention (n=12): One individual nutrition counseling session and three 
IBD-AID-specific cooking classes in addition to usual care 
•  Control (n=5): Usual care 
•  Study duration: 2 months after 70% adherence to the diet for IBD-AID 
participants, and 2 months after baseline for control participants 
 
OUTCOME MEASURES 
1.  Reduction in symptomology, as measured by the validated Harvey 
Bradshaw Index (HBI) 
2.  Reduction in the need of immunomodulatory and anti-inflammatory 
medications 
3.  Normalizing trend in circulating inflammatory markers (i.e., CRP and ESR), 
albumin, and hematocrit 
 
FEASIBILITY MEASURES 
1.  Participant retention 
2.  Dietary compliance 
3.  Participants’ self-assessments of difficulty in maintaining the diet 
•  A total of 15 enrolled patients with confirmed diagnosis of Crohn’s Disease, 5 in observation arm, 10 in intervention arm.  
  -Average Age: 51 years 
•  Harvey-Bradshaw Index (HBI) scores dropped an average of 2.2 and 1.3 points for the Intervention group and Control 
group, respectively. 
This research was supported by the UMMS Center for Applied Nutrition?
•  Eliminating problem foods from the diet is often manageable for patients, 
but adding unfamiliar foods (particularly probiotics, such as plain yogurt, 
kimchi, miso, sauerkraut, etc.), is a huge barrier to maintaining 
compliance.  
•  May be a partial reflection of the Western food and dieting culture  
 
•  Despite lack of statistical significance, the two patients who exhibited 
normalizing lab values, in combination with their improved HBI scores, 
suggest the possibility of a real and meaningful benefit from IBD-AID for 
those able to comply with the dietary and lifestyle changes. 
 
•  Feasibility: The considerable loss to follow-up in this study may reflect a 
variety of issues:  
•  The diet itself, which should be re-examined to simplify or reframe 
in order to maximize generalizability and access for a greater 
percentage of IBD patients 
•  The medical and psychosocial complexity of IBD patients  
•  These limitations highlight the need for additional support and close 
follow-up when it comes to facilitating lifestyle change in this 
population.  
RESULTS 
DISCUSSION 
 BACKGROUND 
•  33% of patients with complete follow-up and on IBD medication at baseline (5-aminosalicylates, antibiotics, 
glucocorticoids, immunomodulators, and biologic therapies) (n=9) decreased doses of or discontinued these 
medications.  
Table 1: Dietary Components Analysis - Significant increases in prebiotic and favorable dietary components, and decrease in adverse 
foods for the group as a whole (paired t-test values 0.0016, 0.0344, 0.0085, and 0.0014, respectively).  
“Tom” is a 38 year old with Crohn’s disease and IBS, as well as clinical depression, currently on five psychoactive drugs. He 
is unemployed and unable to do his own shopping, relying on fast food and take out meals. But at intake, Tom is motivated 
to change as he is “at the end of his rope.”  
 However at the first follow-up, he admits that his depression has worsened; he is unable to get out of the house to 
shop for food, and therefore cannot cook.  Another patient in the study expresses willingness to help by providing him with 
meals, but Tom declines, as he is uncomfortable having anyone come to his home.  He does not want to attend any group 
classes, and is increasingly unresponsive to phone calls and texts. Tom is ultimately lost to follow-up, stating he cannot get 
out of the house and does not want anyone coming to see him.  He continues to attend usual care visits with his primary. 
MATERIALS AND METHODS 
 
Vignette 1: A “Not-So-Successful Story” 
Vignette 2: A “Success Story” 
“Sara” (Patient 1, above) is a graduate student with a history of Crohn’s 
disease complicated by strictures, stenotia, and medication failures. She 
lives with her partner, who suffers from IBS. She started the study while in 
a flair, with an HBI score of 11, corresponding with moderate disease. She 
described her health as “Poor.” She and her partner do not cook regularly, 
and their diet consists mostly of simple starches and sugar.  
 At follow-up, after two months on the IBD-AID, Sara feels much 
improved and has considerably more energy. She is now sharing cooking 
duties with her spouse. She reports having no difficulty avoiding adverse 
foods, but adding probiotic foods is more difficult. Sara’s lab values reflect 
her symptomatic improvement, and interestingly, her perception of support 
from her family/spouse increased from 3 to 5, 5 indicating the most 
support. She has also gained insight into how stress and lack of sleep 
impede her healing. 
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The IBD-AID Pyramid 
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•  Feasibility Measures:  
1.  Loss to follow-up rate of 33.3% 
2.  Average “difficulty score” of 3.1 (scale of 1-5, very easy to very difficult)  
CRP ESR Hematocrit 
Figure 1: Lab values mirrored symptomatic improvements in two of our intervention patients, with changes in CRP, ESR, and 
hematocrit levels of -55.9 and -1.4, -30.0 and -15.0, and +5.4 and +0.3, respectively, with corresponding symptomatic improvements 
(HBI scores 11à7 and 8à0, respectively). No significance can be assigned, however, due to low sample size and loss to follow-up.  
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CONCLUSION 
Overall, this small study highlights the need for larger-scale clinical trials in 
order to draft nutritional guidelines for IBD patients and further legitimize the 
utility of preventive clinical nutrition in Western medicine. 
